Brief: Endonovo Therapeutics Inc - Sofpulse, Inc. Will Operate Independently After Planned Spin-Off
19/01/2023 14:10
Jan 19 (Reuters) - Endonovo Therapeutics Inc ENDV.PK :
* ENDONOVO THERAPEUTICS INC - SOFPULSE, INC. WILL OPERATE
INDEPENDENTLY AFTER PLANNED SPIN-OFF
* ENDONOVO - NEW CO WILL BE OVERSEEN BY IRA WEISBERG,
CURRENT
PRESIDENT & CHIEF COMMERCIAL OFFICER OF CO'S MEDICAL DIVISION
* ENDONOVO THERAPEUTICS INC - SPIN-OFF IS EXPECTED TO RESULT
IN A
PRE-MONEY VALUATION OF SOFPULSE, INC. IN EXCESS OF $50 MILLION
Source text for Eikon: ID:nGNX40ksBG
Further company coverage: ENDV.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Endonovo Therapeutics
See all newsBrief: Endonovo To Sell SofPulse Brand Business And IP To SofPulse Inc For A Minimum Of $50 Million
Brief: Endonovo’S Sofpulse® Nears Final Stages To Receive Taiwan FDA License To Distribute In Taiwan
Brief: Endonovo Therapeutics Inc - Sofpulse, Inc. Will Operate Independently After Planned Spin-Off
Brief: Endonovo Therapeutics Details Plan To Spin Off Medical Device Division As A Listed Public Company
Brief: Endonovo Announces Plan To Explore Strategic Alternatives For Its Sofpulse Medical Device Assets